Expression of nectin-4 in papillary renal cell carcinoma

URN to cite this document:: urn:nbn:de:bvb:355-epub-578019
DOI to cite this document:: 10.5283/epub.57801

Zschäbitz, Stefanie ; Mikuteit, Marie ; Stöhr, Christine ; Herrmann, Edwin ; Polifka, Iris ; Agaimy, Abbas ; Trojan, Lutz ; Ströbel, Philipp ; Becker, Frank ; Wülfing, Christian ; Barth, Peter ; Stöckle, Michael ; Staehler, Michael ; Stief, Christian ; Haferkamp, Axel ; Hohenfellner, Markus ; Duensing, Stefan ; Macher-Göppinger, Stephan ; Wullich, Bernd ; Noldus, Joachim ; Brenner, Walburgis ; Roos, Frederik C. ; Walter, Bernhard ; Otto, Wolfgang ; Burger, Maximilian ; Schrader, Andres Jan ; Hartmann, Arndt ; Erlmeier, Franziska ; Steffens, Sandra

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 29 Feb 2024 13:02

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Background Nectin-4 contributes to tumor proliferation, lymphangiogenesis and angiogenesis in malignant tumors and is an emerging target in tumor therapy. In renal cell carcinoma (RCC) VEGF-directed tyrosine kinase inhibitors and checkpoint inhibitors are currently treatments of choice. Enfortumab vedotin-ejf (EV) is an antibody drug conjugate that targets Nectin-4. The aim of our study was to ...